- Home
- ALT vs HQL Comparison
ALT vs HQL Comparison
Compare ALT & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALT | HQL |
|---|---|---|
| Founded | 1997 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 492.8M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALT | HQL |
|---|---|---|
| Price | $3.55 | $15.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 128.7K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $756,308.50 | N/A |
| P/E Ratio | ★ N/A | $20.20 |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.91 | $10.55 |
| 52 Week High | $7.73 | $17.80 |
Technical Indicators
Market Signals| Indicator | ALT | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 32.38 |
| Support Level | $3.39 | $15.67 |
| Resistance Level | $4.25 | $17.51 |
| Average True Range (ATR) | 0.24 | 0.29 |
| MACD | -0.10 | -0.12 |
| Stochastic Oscillator | 13.55 | 10.42 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.